FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026016207> ?p ?o ?g. }

• W2026016207 endingPage "S517" @default.
• W2026016207 startingPage "S517" @default.
• W2026016207 abstract "Purpose/Objective(s)Recurrent, high-risk head and neck (HN) cancer patients experience poor local control and survival with the current treatment options such as external beam radiation, surgery or chemotherapy. Evaluation of the feasibility and efficacy of reirradiation using contemporary radiation techniques is limited. Recognizing the need for further investigation in these high-risk patients, we developed a pilot study of salvage surgery with adjuvant brachytherapy using Cs-131 implants. Here we describe the long-term outcomes of the novel use of Cs-131 brachytherapy with concurrent salvage surgery.Materials/MethodsEligible patients were those with recurrent biopsy-proven HN cancer after prior definitive RT or patients with a new squamous cell primary carcinoma (Stage III/IV) of HN arising within previously irradiated fields. The recurrence was defined as recurrent Stage III-IV, but surgically resectable. Patients underwent a gross total resection of the tumor with implantation of Cs-131 brachytherapy seeds. Radiation seeds were implanted at 0.5-1 cm distances, covering the tumor bed with 80 Gy at 0.5 cm. Rates of overall survival (OS), locoregional recurrence free survival (LRFS), and disease-free survival (DFS) were analyzed using Kaplan Meier analysis. Recurrence was evaluated by clinical examination and confirmed by contrast CT and/or FDG-PET. Rates of radiation-induced toxicity were analyzed according to the Radiation Therapy Oncology Group toxicity criteria. The radiation exposure to the radiation oncology team, surgery team and remaining staff was measured as a part of this study.ResultsBetween 2010 and 2013, a total of 19 patients were enrolled. The majority of histology was squamous cell carcinoma (10/19). One patient had gross residual disease following surgical resection. With follow-up up to 44 months (median 15, range 1-44 months), 9 patients developed another recurrence or progression of HN cancer, including the patient who had gross residual disease after attempted surgery. In 5 of these 9 cases, the failure was locoregional and in 2 patients, it was isolated distant failure. One patient was found to have simultaneous locoregional and distant progression of disease. Median overall survival is 15 months and disease free survival is 12 months. The 6, 12 and 18 month OS was 77%, 71% and 45%. The 6, 12 and 18 month LRFS was 69%, 62% and 52%. The 6, 12 and 18 month DFS was 61%, 48% and 40%. Two patients developed Grade 3 toxicity; all other complications were Grade 1-2 with no Grade 4 or 5 complications. The exposure rate with Cs-131 was found to be acceptable.ConclusionsCompared to prior literature, our study shows that use of concurrent Cs-131 brachytherapy achieves excellent rates of local control and survival. In addition, the implant related exposure to staff was minimal, and there was no grade 4 or 5 toxicity despite re-irradiation in most patients. Purpose/Objective(s)Recurrent, high-risk head and neck (HN) cancer patients experience poor local control and survival with the current treatment options such as external beam radiation, surgery or chemotherapy. Evaluation of the feasibility and efficacy of reirradiation using contemporary radiation techniques is limited. Recognizing the need for further investigation in these high-risk patients, we developed a pilot study of salvage surgery with adjuvant brachytherapy using Cs-131 implants. Here we describe the long-term outcomes of the novel use of Cs-131 brachytherapy with concurrent salvage surgery. Recurrent, high-risk head and neck (HN) cancer patients experience poor local control and survival with the current treatment options such as external beam radiation, surgery or chemotherapy. Evaluation of the feasibility and efficacy of reirradiation using contemporary radiation techniques is limited. Recognizing the need for further investigation in these high-risk patients, we developed a pilot study of salvage surgery with adjuvant brachytherapy using Cs-131 implants. Here we describe the long-term outcomes of the novel use of Cs-131 brachytherapy with concurrent salvage surgery. Materials/MethodsEligible patients were those with recurrent biopsy-proven HN cancer after prior definitive RT or patients with a new squamous cell primary carcinoma (Stage III/IV) of HN arising within previously irradiated fields. The recurrence was defined as recurrent Stage III-IV, but surgically resectable. Patients underwent a gross total resection of the tumor with implantation of Cs-131 brachytherapy seeds. Radiation seeds were implanted at 0.5-1 cm distances, covering the tumor bed with 80 Gy at 0.5 cm. Rates of overall survival (OS), locoregional recurrence free survival (LRFS), and disease-free survival (DFS) were analyzed using Kaplan Meier analysis. Recurrence was evaluated by clinical examination and confirmed by contrast CT and/or FDG-PET. Rates of radiation-induced toxicity were analyzed according to the Radiation Therapy Oncology Group toxicity criteria. The radiation exposure to the radiation oncology team, surgery team and remaining staff was measured as a part of this study. Eligible patients were those with recurrent biopsy-proven HN cancer after prior definitive RT or patients with a new squamous cell primary carcinoma (Stage III/IV) of HN arising within previously irradiated fields. The recurrence was defined as recurrent Stage III-IV, but surgically resectable. Patients underwent a gross total resection of the tumor with implantation of Cs-131 brachytherapy seeds. Radiation seeds were implanted at 0.5-1 cm distances, covering the tumor bed with 80 Gy at 0.5 cm. Rates of overall survival (OS), locoregional recurrence free survival (LRFS), and disease-free survival (DFS) were analyzed using Kaplan Meier analysis. Recurrence was evaluated by clinical examination and confirmed by contrast CT and/or FDG-PET. Rates of radiation-induced toxicity were analyzed according to the Radiation Therapy Oncology Group toxicity criteria. The radiation exposure to the radiation oncology team, surgery team and remaining staff was measured as a part of this study. ResultsBetween 2010 and 2013, a total of 19 patients were enrolled. The majority of histology was squamous cell carcinoma (10/19). One patient had gross residual disease following surgical resection. With follow-up up to 44 months (median 15, range 1-44 months), 9 patients developed another recurrence or progression of HN cancer, including the patient who had gross residual disease after attempted surgery. In 5 of these 9 cases, the failure was locoregional and in 2 patients, it was isolated distant failure. One patient was found to have simultaneous locoregional and distant progression of disease. Median overall survival is 15 months and disease free survival is 12 months. The 6, 12 and 18 month OS was 77%, 71% and 45%. The 6, 12 and 18 month LRFS was 69%, 62% and 52%. The 6, 12 and 18 month DFS was 61%, 48% and 40%. Two patients developed Grade 3 toxicity; all other complications were Grade 1-2 with no Grade 4 or 5 complications. The exposure rate with Cs-131 was found to be acceptable. Between 2010 and 2013, a total of 19 patients were enrolled. The majority of histology was squamous cell carcinoma (10/19). One patient had gross residual disease following surgical resection. With follow-up up to 44 months (median 15, range 1-44 months), 9 patients developed another recurrence or progression of HN cancer, including the patient who had gross residual disease after attempted surgery. In 5 of these 9 cases, the failure was locoregional and in 2 patients, it was isolated distant failure. One patient was found to have simultaneous locoregional and distant progression of disease. Median overall survival is 15 months and disease free survival is 12 months. The 6, 12 and 18 month OS was 77%, 71% and 45%. The 6, 12 and 18 month LRFS was 69%, 62% and 52%. The 6, 12 and 18 month DFS was 61%, 48% and 40%. Two patients developed Grade 3 toxicity; all other complications were Grade 1-2 with no Grade 4 or 5 complications. The exposure rate with Cs-131 was found to be acceptable. ConclusionsCompared to prior literature, our study shows that use of concurrent Cs-131 brachytherapy achieves excellent rates of local control and survival. In addition, the implant related exposure to staff was minimal, and there was no grade 4 or 5 toxicity despite re-irradiation in most patients. Compared to prior literature, our study shows that use of concurrent Cs-131 brachytherapy achieves excellent rates of local control and survival. In addition, the implant related exposure to staff was minimal, and there was no grade 4 or 5 toxicity despite re-irradiation in most patients." @default.
• W2026016207 created "2016-06-24" @default.
• W2026016207 creator A5015906798 @default.
• W2026016207 creator A5017699584 @default.
• W2026016207 creator A5023841821 @default.
• W2026016207 creator A5025036370 @default.
• W2026016207 creator A5033578637 @default.
• W2026016207 creator A5041648206 @default.
• W2026016207 creator A5043314766 @default.
• W2026016207 creator A5043935006 @default.
• W2026016207 creator A5075567509 @default.
• W2026016207 date "2014-09-01" @default.
• W2026016207 modified "2023-09-27" @default.
• W2026016207 title "Significantly Improved Local Control With the Use of Cesium-131 Brachytherapy in High-Risk and Recurrent Head and Neck (HN) Cancers: Long-Term Results of a Pilot Study" @default.
• W2026016207 doi "https://doi.org/10.1016/j.ijrobp.2014.05.1582" @default.
• W2026016207 hasPublicationYear "2014" @default.
• W2026016207 type Work @default.
• W2026016207 sameAs 2026016207 @default.
• W2026016207 citedByCount "0" @default.
• W2026016207 crossrefType "journal-article" @default.
• W2026016207 hasAuthorship W2026016207A5015906798 @default.
• W2026016207 hasAuthorship W2026016207A5017699584 @default.
• W2026016207 hasAuthorship W2026016207A5023841821 @default.
• W2026016207 hasAuthorship W2026016207A5025036370 @default.
• W2026016207 hasAuthorship W2026016207A5033578637 @default.
• W2026016207 hasAuthorship W2026016207A5041648206 @default.
• W2026016207 hasAuthorship W2026016207A5043314766 @default.
• W2026016207 hasAuthorship W2026016207A5043935006 @default.
• W2026016207 hasAuthorship W2026016207A5075567509 @default.
• W2026016207 hasBestOaLocation W20260162071 @default.
• W2026016207 hasConcept C141071460 @default.
• W2026016207 hasConcept C143998085 @default.
• W2026016207 hasConcept C2776530083 @default.
• W2026016207 hasConcept C2776694085 @default.
• W2026016207 hasConcept C2777416452 @default.
• W2026016207 hasConcept C2777863537 @default.
• W2026016207 hasConcept C2780775027 @default.
• W2026016207 hasConcept C3018411727 @default.
• W2026016207 hasConcept C509974204 @default.
• W2026016207 hasConcept C71924100 @default.
• W2026016207 hasConceptScore W2026016207C141071460 @default.
• W2026016207 hasConceptScore W2026016207C143998085 @default.
• W2026016207 hasConceptScore W2026016207C2776530083 @default.
• W2026016207 hasConceptScore W2026016207C2776694085 @default.
• W2026016207 hasConceptScore W2026016207C2777416452 @default.
• W2026016207 hasConceptScore W2026016207C2777863537 @default.
• W2026016207 hasConceptScore W2026016207C2780775027 @default.
• W2026016207 hasConceptScore W2026016207C3018411727 @default.
• W2026016207 hasConceptScore W2026016207C509974204 @default.
• W2026016207 hasConceptScore W2026016207C71924100 @default.
• W2026016207 hasIssue "1" @default.
• W2026016207 hasLocation W20260162071 @default.
• W2026016207 hasOpenAccess W2026016207 @default.
• W2026016207 hasPrimaryLocation W20260162071 @default.
• W2026016207 hasRelatedWork W1989116149 @default.
• W2026016207 hasRelatedWork W1993267564 @default.
• W2026016207 hasRelatedWork W2026862380 @default.
• W2026016207 hasRelatedWork W2040280396 @default.
• W2026016207 hasRelatedWork W2053149218 @default.
• W2026016207 hasRelatedWork W2088214291 @default.
• W2026016207 hasRelatedWork W2294357262 @default.
• W2026016207 hasRelatedWork W2529376761 @default.
• W2026016207 hasRelatedWork W2972960287 @default.
• W2026016207 hasRelatedWork W4220908969 @default.
• W2026016207 hasVolume "90" @default.
• W2026016207 isParatext "false" @default.
• W2026016207 isRetracted "false" @default.
• W2026016207 magId "2026016207" @default.
• W2026016207 workType "article" @default.